The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

Tiempo de lectura: < 1 minuto
¡Haz clic para calificar esta publicación!
No Comments

Sorry, the comment form is closed at this time.